A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story
AS Bandyopadhyay, S Zipursky - The Lancet Infectious Diseases, 2023 - thelancet.com
The recent detection of vaccine-derived poliovirus (VDPV) in London (UK) and a case of
paralytic polio in New York (USA) have highlighted how the scourge of poliomyelitis has not …
paralytic polio in New York (USA) have highlighted how the scourge of poliomyelitis has not …
Controlled human infection models to accelerate vaccine development
RKM Choy, AL Bourgeois… - Clinical Microbiology …, 2022 - Am Soc Microbiol
The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …
Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3
MT Yeh, M Smith, S Carlyle, JL Konopka-Anstadt… - Nature, 2023 - nature.com
Vaccination with Sabin, a live attenuated oral polio vaccine (OPV), results in robust intestinal
and humoral immunity and has been key to controlling poliomyelitis. As with any RNA virus …
and humoral immunity and has been key to controlling poliomyelitis. As with any RNA virus …
Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine
Although there have been no cases of serotype 2 wild poliovirus for more than 20 years,
transmission of serotype 2 vaccine-derived poliovirus (VDPV2) and associated paralytic …
transmission of serotype 2 vaccine-derived poliovirus (VDPV2) and associated paralytic …
Climate change threatens our health and survival within decades
A Costello, M Romanello, S Hartinger… - The Lancet, 2023 - thelancet.com
Climate change harms health in all populations. 1 Heatrelated illness and deaths are
increasing worldwide, from heatstroke, adverse pregnancy outcomes, worsened kidney …
increasing worldwide, from heatstroke, adverse pregnancy outcomes, worsened kidney …
[HTML][HTML] Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
Background The effectiveness of the second BNT162b2 (Pfizer–BioNTech) mRNA COVID-
19 booster vaccine dose (ie, fourth inoculation) is well established, but its safety has yet to …
19 booster vaccine dose (ie, fourth inoculation) is well established, but its safety has yet to …
[HTML][HTML] Enabling accelerated vaccine roll-out for public health emergencies of international concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience
GR Macklin, C Peak, M Eisenhawer, F Kurji, O Mach… - Vaccine, 2023 - Elsevier
To address the evolving risk of circulating vaccine-derived poliovirus type 2 (cVDPV2),
Global Polio Eradication Initiative (GPEI) partners are working closely with countries to …
Global Polio Eradication Initiative (GPEI) partners are working closely with countries to …
Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised …
AL Wilkinson, K Zaman, M Hoque… - The Lancet Infectious …, 2023 - thelancet.com
Background Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
The Picornaviridae Family: Knowledge Gaps, Animal Models, Countermeasures, and Prototype Pathogens
R Andino, K Kirkegaard, A Macadam… - The Journal of …, 2023 - academic.oup.com
Picornaviruses are nonenveloped particles with a single-stranded RNA genome of positive
polarity. This virus family includes poliovirus, hepatitis A virus, rhinoviruses, and …
polarity. This virus family includes poliovirus, hepatitis A virus, rhinoviruses, and …
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two …
I De Coster, I Leroux-Roels, AS Bandyopadhyay… - The Lancet, 2021 - thelancet.com
Background Two novel type 2 oral poliovirus vaccine (OPV2) candidates, novel OPV2-c1
and novel OPV2-c2, designed to be more genetically stable than the licensed Sabin …
and novel OPV2-c2, designed to be more genetically stable than the licensed Sabin …